Protagonist Therapeutics, Inc. Common Stock (NASDAQ: PTGX) last traded at $138.49, down 4.41% on the session. The quote above updates while this page is open; the figures below are drawn from Protagonist Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Protagonist Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker PTGX. Its market capitalisation is $8.96 billion.
Valuation measures for Protagonist Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $8.96B |
|---|---|
| Enterprise value | $8.59B |
| P/E ratio | 134.46 |
| Price / sales | 31.78 |
| Price / book | 10.65 |
| Beta |
| 0.83 |
Trailing-twelve-month figures tagged in Protagonist Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $281.99M |
|---|---|
| Net income (TTM) | $82.91M |
| EPS (TTM) | $1.03 |
| Operating margin | 20.69% |
| Return on equity | 9.85% |
| Cash | $420.08M |
Range and volume for PTGX over the past 52 weeks.
| 52-week high | $160.81 |
|---|---|
| 52-week low | $73.08 |
| Volume | 1.03M |
| Average volume | 630.3K |
| Previous close | $144.88 |
Invest a chosen dollar amount in Protagonist Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell PTGX.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.